RxDoctor Payments Data

John Gumina, MD

Family Medicine · Freehold, NJNPI 1831169515

Payments from drug & device makers

$11,864in general payments, 2019–2025

Across 795 payments — averaging $14.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • AstraZeneca$2K
  • Novo Nordisk$2K
  • Lilly USA, LLC$1K
  • Boehringer Ingelheim$853
  • Amarin Pharma, Inc.$636
  • plus $4K from 39 others

What the payments were for

  • Food & beverage$11,846100%
  • Education$180%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,864 in reported general payments places this provider in the 95th percentile of 2,084 family medicine providers in New Jersey.

See all family medicine providers in New Jersey

Medicare billing

Part B allowed, 2024
$184,274
Medicare patients
323
Services billed
3,258

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide63$87,499
FarxigaDapagliflozin Propanediol68$80,649
JardianceEmpagliflozin56$65,425
EliquisApixaban61$57,356
RybelsusSemaglutide23$38,263
ShingrixVaricella-Zoster Ge/As01b/Pf175$37,122
JanuviaSitagliptin Phosphate43$32,607
JanumetSitagliptin Phos/Metformin Hcl23$30,655
Trelegy ElliptaFluticasone/Umeclidin/Vilanter34$27,738
MresviaRsv Vaccine, Pref, Mrna/Pf80$23,956
MounjaroTirzepatide12$21,863
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog12$20,503
ArexvyRsvpref3 Antigen/As01e/Pf66$19,501
MyrbetriqMirabegron15$18,589
Tresiba Flextouch U-200Insulin Degludec25$14,331

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$1,722$125,76286 claims
GSKShingrix, Trelegy Ellipta, Arexvy$258$84,361275 claims
AstraZenecaFarxiga$1,731$80,64968 claims
Boehringer IngelheimJardiance$853$65,42556 claims
MerckJanuvia, Janumet$271$63,26266 claims
PfizerEliquis$307$57,35661 claims
Lilly USA, LLCMounjaro$1,163$21,86312 claims
Astellas Pharma US IncMyrbetriq$99$18,58915 claims
AbbVieSynthroid$1,851$5,23884 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$14$3,717319 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,084 family medicine providers in New Jersey.

Other family medicine in Freehold

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →